Evonik Evonik

X

Find the latest Drugs in Development and Pipeline Prospector News of Bryn Pharma.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Bryn Pharma
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
Raleigh, North Carolina
Telephone
Telephone
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Utuly (epinephrine) is a nonselective alpha- and beta-adrenergic receptor agonist. Through its action on alpha-adrenergic receptors, it reduces vasodilation and increases vascular permeability that occurs during anaphylaxis.


Lead Product(s): Epinephrine

Therapeutic Area: Immunology Product Name: Utuly

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 24, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Utuly, an epinephrine nasal spray, for the treatment of anaphylaxis. It is designed to provide patients with a life-saving treatment that is needle free, fits in a pocket, is easy to use, and complies with practice parameters.


Lead Product(s): Epinephrine

Therapeutic Area: Immunology Product Name: Utuly

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 13, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Proceeds from the financing will be used to fund the remaining development and regulatory approval activities, and pre-launch commercialization program for BRYN-NDS1C, Bryn's bi-dose epinephrine nasal spray.


Lead Product(s): Epinephrine

Therapeutic Area: Immunology Product Name: BRYN-NDS1C

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $26.0 million Upfront Cash: Undisclosed

Deal Type: Financing August 04, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The preclinical results described in the publications were used to support the advancement of BRYN-NDS1C into the human clinical trial program currently underway.


Lead Product(s): Epinephrine

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 10, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Intranasal (IN) delivery of epinephrine from Bryn's needle-free Bi-dose Epinephrine Nasal Spray was comparable to intramuscular (IM) injection in pharmacokinetics, pharmacodynamics, and safety.


Lead Product(s): Epinephrine

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 06, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY